Medico Oncologo

Buenos Aires
Rodrigo Sanchez Roger retweeted
⚡️ FDA approves belzutifan + lenvatinib for advanced ccRCC after PD-1/PD-L1 inhibitor therapy. Based on LITESPARK-011: median PFS 14.6 vs 10.6 months (HR 0.74) vs cabozantinib. OS not significantly different at final analysis. #KidneyCancer @OncoAlert fda.gov/drugs/resources-info…
5
17
48
2,399
Rodrigo Sanchez Roger retweeted
Empezando #CursoIA conjunto @SAIA_AR + @aaoncoclinica
1
3
11
384
Rodrigo Sanchez Roger retweeted
1
3
3
113
Rodrigo Sanchez Roger retweeted
Un gran día en la @ANacionalMed 🇲🇽👩🏻‍⚕️💙educación médica continua en #cancerdeprostata #cancerdevejiga @incmnszmx @INCMNSZ_Uronco @INCMNSZ_DirInv presente!
7
5
70
1,770
Rodrigo Sanchez Roger retweeted
Honored to be selected as an #ASTRO26 Social Champion! Thank you @ASTRO_org for this opportunity and congratulations to all my fellow Social Champions. It’s a privilege to join such an inspiring group and help share the science, innovation, and conversations shaping our field. Proud to represent #SATRO Argentina 🇦🇷 and Latin American radiation oncology @Solar_Latam on this global stage. Boston! 🇺🇸 @IAbuGheidaMD @TylerSbrt @DrewMoghanaki @OncoAlert @lauren_henke @nadinehousri @TugceKutukMD @AlexisNarvaezMD @P_Shams_ @sarthakshah097 @CJTsaiMDPhD @CancerNetwrk
Introducing the ASTRO 2026 Social Champions! The #ASTRO26 Social Champions serve as Annual Meeting ambassadors on X and other social channels during the conference. They will share important science and topics of interest throughout the meeting. Follow ASTRO and our Social Champions on X to see highlights of the Annual Meeting and use the hashtag #ASTRO26 to join the discussions. Meet our 2026 Social Champions: bit.ly/4zgEwng @DrewMoghanaki @themednet @nadinehousri @IAbuGheidaMD @lauren_henke @TugceKutukMD @ARRO_org @sarthakshah097 @P_Shams_ @CJTsaiMDPhD @TylerSbrt @barrosonco @AlexisNarvaezMD @OncoAlert @CancerNetwrk
3
3
22
1,080
Rodrigo Sanchez Roger retweeted
Empacando #UroAcademy26 junto a @oncourologiaarg!! Feliz de poder estar en este gran evento. @aaoncoclinica
1
3
14
341
Rodrigo Sanchez Roger retweeted
No te podes perder este curso!! @aaoncoclinica ➕ @SAIA_AR IA para oncólogos! #AAOCDigital
1
5
9
377
Rodrigo Sanchez Roger retweeted
🤔 ¿Quién tiene razón? En urooncología, muchas decisiones no tienen una única respuesta. 🟠 Controversias 🟠 Expertos 🟠 Debate 🟠 Votación en vivo 📅 16/09 | 🎥 Streaming gratuito 📝 Registro sin costo + certificado Escuchá. Discutí. Votá. 👉 forms.gle/jqPRoA2yaBBmRrCC9
Made with AI
1
4
230
Rodrigo Sanchez Roger retweeted
📌 VIRO 2026 – Global Voices in Renal Oncology | Day 1 - Session 2 The second session of #VIRO2026 – Global Voices in Renal Oncology continued with a practical and globally focused discussion on renal cancer care, covering treatment after first-line failure, disparities in access, diagnostic strategies, next-generation imaging, and challenges in kidney cancer clinical trials. Maria Bourlon (@BourlonMaite) discussed what to do after combination therapy failure in the first line, focusing on treatment considerations beyond initial therapy. Fernando Cotait Maluf shared a Latin American perspective on renal cell carcinoma diagnosis and treatment, while Federico Losco explored the hidden burden of kidney cancer, including epidemiology, access gaps, and challenges in low- and middle-income countries. The session then turned to diagnosis and imaging. Ying-Bei Chen (@Unclassified1) discussed renal tumor biopsy interpretation strategies and challenges, while Janaki Sharma explored next-generation imaging in clear cell RCC. Finally, Fed Ghali (@FedGhali) examined common pitfalls in oncology trials within kidney cancer and beyond, bringing the session to a close with a focus on improving clinical research and evidence generation. The session brought together clinical, diagnostic, and global perspectives to address key challenges in renal oncology and support more informed, personalized cancer care. 🔴 Live sessions available here: nitter.net/i/broadcasts/1RJjpbVkk… 🔗 Learn more about VIRO 2026 – Global Voices in Renal Oncology: oncodaily.com/viro-2026-glob… #VIRO2026
1
8
20
1,272
Auspicio institucional link de inscripción bioinfo.qb.fcen.uba.ar/onco2….
3
5
327
Rodrigo Sanchez Roger retweeted
Link de inscripción: aaoc.org.ar/inteligenciaarti…
1
1
55
Rodrigo Sanchez Roger retweeted
Excelente discusión sobre oligometastasis en cancer renal. Focal vs sistémico 🤝 #Mesaza @aaoncoclinica @EAaoc
ESTÁNDARES TERAPÉUTICOS 2026 Tumores Urológicos
1
4
351
Rodrigo Sanchez Roger retweeted
⚡️ First clinical validation of the EAU definitions of BCG failure in NMIBC (n=776). BCG-refractory disease showed the highest progression rates — up to 46% at 5 years. Early BCG-unresponsive recurrences conveyed similar progression risk to BCG-refractory disease, supporting their inclusion in this category. Prognostically informative definitions that can support clinical decision-making. euoncology.europeanurology.c… #BladderCancer @EurUrolOncol
2
13
30
1,927
POST CHICAGO 2026: TUMORES GINECOLÓGICOS Coordinan: Dres Matías Cortés y Belén García Giner Cirugía – Dr X.Taype Radioterapia – Dr M. Barros Cérvix, vulva y vagina – Dra B. Montenegro Ovario – Dr Mauro Orlando Endometrio – Dra Mariana Savignano Nuevas Drogas – Dr Rodrigo Sánchez
1
3
4
306
Formulario de inscripción docs.google.com/forms/d/e/1F…
1
2
165
Rodrigo Sanchez Roger retweeted
⚡️ Histological subtypes of urothelial carcinoma — micropapillary, plasmacytoid, sarcomatoid, squamous — don't fit the one-size-fits-all treatment paradigm. Each carries distinct biology, is often understaged on TURBT, and shows variable response to standard systemic therapy. sciencedirect.com/science/ar… #BladderCancer
5
44
91
8,503